SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials

Xiaoming Jia, Paras B. Mehta, Yumei Ye, Mahboob Alam, Yochai Birnbaum, Mandeep Bajaj

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Purpose of Review: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to exert benefit on cardiac outcomes. In this review, we provide updates on available clinical data, studies on potential mechanisms for the CV effects, as well as discuss potential clinical implications of these new findings. Recent Findings: Since the publications of the EMPA-REG and CANVAS trials, large multi-national cohort studies have further shown the cardioprotective effects of SGLT2i. Moreover, new studies examining SGLT2i action on sodium-hydrogen exchanger proteins in both the heart and the kidney, on myocardial energetics and impact on inflammation and atherosclerosis continue to shed light on the multitude of pleotropic effects of these agents. Summary: Though more data is needed to substantiate the safety and efficacy, SGLT2i should be considered as a valuable therapy to help reduce CV risk in patients with diabetes. Ultimately, SGLT2i may have utility in preventing progression to diabetes or providing CV protection in patients who do not have diabetes.

Original languageEnglish (US)
Article number63
JournalCurrent Diabetes Reports
Issue number9
StatePublished - Sep 1 2018
Externally publishedYes


  • Cardiovascular outcomes
  • SGLT2 inhibitor
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials'. Together they form a unique fingerprint.

Cite this